Bio

Hongbo Lu, Ph.D., is a Partner of Vivo Capital. Dr. Lu has close to 20 years of healthcare investment experience in both public securities and private companies. Prior to joining Vivo, she served as a Managing Partner at Lilly Asia Ventures (LAV). Prior to that, she served as a Managing Director at OrbiMed Advisors. Over her investment career, Dr. Lu has invested extensively in both China and the U.S. She previously served on the boards of Turning Point Therapeutics (TPTX), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), Passage (PASG, observer), and was extensively involved in the company incubations of ADARx, Alpiscience, Geneception, Perfuse, Terns, and Ronovo since inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was involved in biotech start-ups in the Bay Area previously. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.